Roche’s Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study

two couple are showing half full and half empty side of water glass with their fingers
Click here to view original web page at scrip.pharmaintelligence.informa.com

two couple are showing half full and half empty side of water glass with their fingers

Executive Summary

Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.

Register for our free email digests:

two couple are showing half full and half empty side of water glass with their fingers

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.